Hester Biosciences Ltd
NSE:HESTERBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (4.9), the stock would be worth ₹1 809.4 (9% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4.5 | ₹1 655.6 |
0%
|
| 3-Year Average | 4.9 | ₹1 809.4 |
+9%
|
| 5-Year Average | 6 | ₹2 225 |
+34%
|
| Industry Average | 4.1 | ₹1 507.27 |
-9%
|
| Country Average | 2.6 | ₹966.89 |
-42%
|
Forward P/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Hester Biosciences Ltd
NSE:HESTERBIO
|
14.1B INR | 4.5 | 34.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.5B USD | 5.9 | 86.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.2B USD | 5 | 23.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
159.9B USD | 5.4 | 18.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 9 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
72.5B USD | 5.1 | 16.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
40.6B EUR | 11.5 | 37 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.6B AUD | 2.7 | 29.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.6 |
| 70th Percentile | 4.6 |
| Max | 56 363.4 |
Other Multiples
Hester Biosciences Ltd
Glance View
Hester Biosciences Ltd. is a holding company, which engages in the manufacture and trade of poultry vaccines and animal health products. The company is headquartered in Ahmedabad, Gujarat and currently employs 584 full-time employees. Its segments include Poultry division and Animal division. The company provides over 40 products across poultry vaccines (live and inactivated), animal vaccines (live and inactivated), health products and diagnostics. Its product range includes vaccines, drugs, feed supplements and disinfectants. The company manufactures over two live vaccines for large animals, including Peste des Petits Ruminants (PPR) Live vaccines and Goat Pox Vaccine. Its offerings include Avian, including Live B1, Live LAS, Live R2B, Live M48, Live FP, Gumboro M1, Gumboro I and Gumboro I+; swine fever vaccines, and animal, including PPR Vaccine-Sungri 96 strain and Brucella abortus (S19) calf Vaccine. The company offers services, such as seromonitoring for poultry farms and mastitis prevention programs for cattle farms.
